Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorpromazine Hydrochloride

FDA-approved product (concentrate, oral), marketed as Chlorpromazine Hydrochloride, Chlorpromazine Hydrochloride Intensol, Promapar and 2 more.

Registered studies
33
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chlorpromazine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conduct disorder
  • Mental or behavioural disorder
  • Nausea and vomiting
  • Porphyria
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with aliphatic side-chain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis75.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorpromazine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorpromazine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.

    NCT07364344 · start 2026-01

    Registered record
    Registry ID
    NCT07364344
    Conditions
    Acute Ischemic Stroke
    Interventions
    Hibernation-like Therapy (Chlorpromazine and Promethazine, C+P)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-01
    Completion
    2026-07
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionHibernation-like Therapy (Chlorpromazine and Promethazine, C+P)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

    NCT06663631 · start 2024-11-09

    Registered record
    Registry ID
    NCT06663631
    Conditions
    Acute Ischemic Stroke
    Interventions
    chlorpromazine and promethazine; Placebo group; endovascular thrombectomy; rt-PA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-11-09
    Completion
    2025-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    Interventionchlorpromazine and promethazine; Placebo group; endovascular thrombectomy; rt-PA
    PhasePhase 1
    Registry statusRecruiting

  • Correlation of Genetic Variations With Clinical Response in Substance Use Disorder

    NCT05833399 · start 2022-11-28

    Registered record
    Registry ID
    NCT05833399
    Conditions
    Substance Use Disorders; Substance Dependence
    Interventions
    Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-11-28
    Completion
    2024-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubstance Use Disorders; Substance Dependence
    InterventionQuetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone
    PhaseNot recorded
    Registry statusUnknown

  • Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

    NCT05433402 · start 2022-07-20

    Registered record
    Registry ID
    NCT05433402
    Conditions
    Colon Cancer Stage III
    Interventions
    ChlorproMAZINE 50 MG; Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2022-07-20
    Completion
    2022-09-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer Stage III
    InterventionChlorproMAZINE 50 MG; Control
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

    NCT05431595 · start 2022-07-19

    Registered record
    Registry ID
    NCT05431595
    Conditions
    Delirium; Epileptics; Neuroleptics
    Interventions
    Haloperidol; Chlorpromazine; Valproate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2022-07-19
    Completion
    2027-02-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Epileptics; Neuroleptics
    InterventionHaloperidol; Chlorpromazine; Valproate; Placebo
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Chlorpromazine and Standard of Care in Glioblastoma

    NCT05190315 · start 2022-01-28

    Registered record
    Registry ID
    NCT05190315
    Conditions
    Glioblastoma Multiforme
    Interventions
    Chlorpromazine; Temozolomide; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-01-28
    Completion
    2024-07-28
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma Multiforme
    InterventionChlorpromazine; Temozolomide; Radiation Therapy
    PhasePhase 1
    Registry statusCompleted

  • A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia

    NCT05039489 · start 2021-09-09

    Registered record
    Registry ID
    NCT05039489
    Conditions
    Schizophrenia
    Interventions
    Antipsychotic drugs; cTBS（the left temporoparietal cortex as the stimulation target）; cTBS （the left cerebellum Crus II as the stimulation target）
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-09-09
    Completion
    2023-11-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAntipsychotic drugs; cTBS（the left temporoparietal cortex as the stimulation target）; cTBS （the left cerebellum Crus II as the stimulation target）
    PhaseNot applicable
    Registry statusCompleted

  • Administration of Chlorpromazine as a Treatment for COVID-19

    NCT04354805 · start 2020-08-01

    Registered record
    Registry ID
    NCT04354805
    Conditions
    COVID-19
    Interventions
    Chlorpromazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2020-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionChlorpromazine
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Comparison of Chlorpromazine or Pentobarbital Premedications for Pediatric Imaging Procedures

    NCT04350528 · start 2020-04-30

    Registered record
    Registry ID
    NCT04350528
    Conditions
    Children Sedation
    Interventions
    Chlorpromazine or Pentobarbital
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-04-30
    Completion
    2020-06-30
    Enrolment
    254

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildren Sedation
    InterventionChlorpromazine or Pentobarbital
    PhaseNot recorded
    Registry statusUnknown

  • Repurposing of Chlorpromazine in Covid-19 Treatment

    NCT04366739 · start 2020-04-29

    Registered record
    Registry ID
    NCT04366739
    Conditions
    COVID-19
    Interventions
    CHLORPROMAZINE (CPZ); Standard of Care (SOC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-04-29
    Completion
    2020-09-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionCHLORPROMAZINE (CPZ); Standard of Care (SOC)
    PhasePhase 3
    Registry statusWithdrawn

  • Repurposing Chlorpromazine in the Treatment of Glioblastoma

    NCT04224441 · start 2019-12-15

    Registered record
    Registry ID
    NCT04224441
    Conditions
    Glioblastoma Multiforme; MGMT-Unmethylated Glioblastoma
    Interventions
    Chlorpromazine Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-12-15
    Completion
    2022-12-15
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma Multiforme; MGMT-Unmethylated Glioblastoma
    InterventionChlorpromazine Pill
    PhasePhase 2
    Registry statusUnknown

  • A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

    NCT04002700 · start 2019-05-06

    Registered record
    Registry ID
    NCT04002700
    Conditions
    Stroke
    Interventions
    Haloperidol; Typical Antipsychotics; Atypical Antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-06
    Completion
    2019-05-31
    Enrolment
    1,234,412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    InterventionHaloperidol; Typical Antipsychotics; Atypical Antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • Bioequivalence Study in Healthy Subjects by Using of Chlorpromazine HCl 100mg Tablets

    NCT06154434 · start 2018-12-06

    Registered record
    Registry ID
    NCT06154434
    Conditions
    Healthy Subject
    Interventions
    Chlorpromazine HCl 100mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-06
    Completion
    2019-02-12
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subject
    InterventionChlorpromazine HCl 100mg Tablets
    PhasePhase 1
    Registry statusCompleted

  • TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting

    NCT03639558 · start 2018-08-28

    Registered record
    Registry ID
    NCT03639558
    Conditions
    Psychiatric Emergency; Aggression; Agitation
    Interventions
    Haloperidol + Promethazine + Chlorpromazine; Haloperidol + Promethazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-08-28
    Completion
    2019-07-07
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychiatric Emergency; Aggression; Agitation
    InterventionHaloperidol + Promethazine + Chlorpromazine; Haloperidol + Promethazine
    PhasePhase 4
    Registry statusCompleted

  • The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.

    NCT03183310 · start 2017-07-01

    Registered record
    Registry ID
    NCT03183310
    Conditions
    Esophageal Reflux
    Interventions
    Chlorpromazine; Multimodal stimulation probe; Placebo - Concentrate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-07-01
    Completion
    2017-10-31
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Reflux
    InterventionChlorpromazine; Multimodal stimulation probe; Placebo - Concentrate
    PhaseNot applicable
    Registry statusUnknown